GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Cyclically Adjusted PS Ratio

Jafron Biomedical Co (SZSE:300529) Cyclically Adjusted PS Ratio : 14.00 (As of Jun. 02, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Cyclically Adjusted PS Ratio?

As of today (2024-06-02), Jafron Biomedical Co's current share price is ¥27.58. Jafron Biomedical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥1.97. Jafron Biomedical Co's Cyclically Adjusted PS Ratio for today is 14.00.

The historical rank and industry rank for Jafron Biomedical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

SZSE:300529' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.85   Med: 11.48   Max: 14.87
Current: 14.24

During the past years, Jafron Biomedical Co's highest Cyclically Adjusted PS Ratio was 14.87. The lowest was 8.85. And the median was 11.48.

SZSE:300529's Cyclically Adjusted PS Ratio is ranked worse than
94.09% of 474 companies
in the Medical Devices & Instruments industry
Industry Median: 2.155 vs SZSE:300529: 14.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jafron Biomedical Co's adjusted revenue per share data for the three months ended in Mar. 2024 was ¥0.914. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ¥1.97 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jafron Biomedical Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Jafron Biomedical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Cyclically Adjusted PS Ratio Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 11.60

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 11.60 11.28

Competitive Comparison of Jafron Biomedical Co's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Jafron Biomedical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Cyclically Adjusted PS Ratio falls into.



Jafron Biomedical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Jafron Biomedical Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=27.58/1.97
=14.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jafron Biomedical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Jafron Biomedical Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.914/115.2271*115.2271
=0.914

Current CPI (Mar. 2024) = 115.2271.

Jafron Biomedical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 95.237 0.000
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201503 0.142 99.900 0.164
201506 0.180 99.500 0.208
201509 0.175 100.500 0.201
201512 0.230 100.600 0.263
201603 0.183 102.200 0.206
201606 0.184 101.400 0.209
201609 0.154 102.400 0.173
201612 0.210 102.600 0.236
201703 0.183 103.200 0.204
201706 0.236 103.100 0.264
201709 0.205 104.100 0.227
201712 0.296 104.500 0.326
201803 0.266 105.300 0.291
201806 0.305 104.900 0.335
201809 0.318 106.600 0.344
201812 0.401 106.500 0.434
201903 0.372 107.700 0.398
201906 0.446 107.700 0.477
201909 0.391 109.800 0.410
201912 0.569 111.200 0.590
202003 0.473 112.300 0.485
202006 0.613 110.400 0.640
202009 0.551 111.700 0.568
202012 0.767 111.500 0.793
202103 0.715 112.662 0.731
202106 0.760 111.769 0.784
202109 0.734 112.215 0.754
202112 1.096 113.108 1.117
202203 0.853 114.335 0.860
202206 1.057 114.558 1.063
202209 0.577 115.339 0.576
202212 0.586 115.116 0.587
202303 0.707 115.116 0.708
202306 0.534 114.558 0.537
202309 0.583 115.339 0.582
202312 0.562 114.781 0.564
202403 0.914 115.227 0.914

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jafron Biomedical Co  (SZSE:300529) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Jafron Biomedical Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines